SCHEMBL5366590

SCHEMBL5366590

Cc1c(Br)ccc2c1C(=Cc1ccc([N+](=O)[O-])o1)C(=O)N2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.55
KMT2A Q03164 9/20 0.55
POLB P06746 8/20 0.55
ALDH1A1 P00352 8/20 0.55
L3MBTL1 Q9Y468 7/20 0.55
MAPT P10636 7/20 0.55
TDP1 Q9NUW8 5/20 0.55
KDM4E B2RXH2 5/20 0.55
NSD2 O96028 1/20 0.55
DNMT1 P26358 1/20 0.55
RECQL P46063 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.48
HTT P42858 2/20 0.48
HPGD P15428 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
RET P07949 4/20 0.48
THRB P10828 3/20 0.47
BLM P54132 1/20 0.47
MCL1 Q07820 1/20 0.47
PIK3CG P48736 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7138197 0.83 KMT2A (0.54) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL5367431 0.83 RET (0.55) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL5364403 0.83 KMT2A (0.56) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL5367226 0.79 PTPN1 (0.44) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL7138230 0.78 PTPN1 (0.43) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL7137036 0.78 METAP1 (0.56) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL5358671 0.76 RET (0.39) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL13044214 0.75 KMT2A (0.67) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL6001821 0.73 POLB (0.64) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL6001824 0.73 POLB (0.64) MEN1KMT2APOLBALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MEN1 3855/4885KMT2A 4060/4885POLB 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.